Simulations Plus, Inc.

NASDAQ:SLP

Medical - Healthcare Information Services

Healthcare
$18.50 +0.11%

+$0.02 today

Market cap
$374.16M
Beta
1.32
P/E (TTM)
-5.9
EPS (TTM)
-$3.12
52W Low $11.09High $21.01

Volume 0.00M

Average 0.35M

SLP Interest Expense

Cost of servicing the company's debt during the period.

Simulations Plus, Inc.NASDAQ: SLP

Interest Expense · Q2 FY2026 · quarter ended Feb 2026

Interest expense remains negative

Q2 FY2026 interest expense was $0, compared with $0 a year earlier. Trailing-twelve-month interest expense was $0.

Context

  • Interest expense amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Interest expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterFeb 2026
$0— QoQ
Last fiscal yearAug 2025
$0— YoY
LTMFeb 2026
$0— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Expense vs competitors

How SLP compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Interest expense amounts to 0.0% of revenue for SLP, versus a peer median of 4.8%.
SLP Competitors
Interest Expense for SLP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DHDefinitive Healthcare Corp.LTM Mar 2026$11.48M USD-14.6%+0.3%4.8%
NAKANakamoto Inc.LTM Mar 2026$11.27M USD+3194.6%—287.6%
CLLSCellectis S.A.LTM Mar 2026$8.49M USD+11.7%+28.9%12.5%
SOPHSOPHiA GENETICS S.A.LTM Mar 2026$5.56M USD+379.5%+92.4%6.9%
OPRXOptimizeRx CorporationLTM Mar 2026$5.15M USD-12.8%—4.8%
NRCNational Research CorporationLTM Mar 2026$5.12M USD+77.2%+57.9%3.7%
AGLAgilon Health, Inc.LTM Mar 2026$3.32M USD-48.3%+14.0%0.1%
ANROAlto Neuroscience, Inc.LTM Mar 2026$2.42M USD+48.5%——
ACIUAC Immune S.A.LTM Mar 2026CHF 156.68K CHF+3.8%-18.7%4.2%
SLPSimulations Plus, Inc.LTM Feb 2026$0 USD——0.0%
KRROKorro Bio, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding SLP) —+11.7%+21.4%4.8%

Competitors are the stored peer set for SLP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Aug 2021
FY2022
Aug 2022
FY2023
Aug 2023
FY2024
Aug 2024
FY2025
Aug 2025
Revenue46.47M53.91M59.58M70.01M79.18M
Cost of Revenue10.6M10.82M11.63M26.86M32.96M
Gross Profit35.87M43.08M47.95M43.15M46.22M
Gross Margin77.2%79.9%80.5%61.6%58.4%
Research & Development4.05M3.21M4.5M5.75M6.88M
Selling, General & Admin20.57M24.97M34.72M31.27M32.85M
Operating Expenses24.61M28.17M39.22M37.02M116.95M
Depreciation & Amortization3.59M3.57M3.84M5.67M8.21M
EBITDA14.7M18.69M13.07M18.08M14.7M
EBITDA Margin31.6%34.7%21.9%25.8%18.6%
Operating Income11.25M14.91M8.73M6.13M(70.73M)
Operating Margin24.2%27.7%14.6%8.8%-89.3%
Interest Income201K717K4.13M4.38M722K
Interest Expense22K0000
Other Income / Expenses(168K)204K2.97M6.28M1.35M
Income Before Tax11.09M15.12M11.7M12.41M(69.38M)
Pre-Tax Margin23.9%28.0%19.6%17.7%-87.6%
Income Tax Expense1.3M2.63M1.73M2.46M(4.66M)
Net Income9.78M12.48M9.96M9.95M(64.72M)
Net Margin21.1%23.2%16.7%14.2%-81.7%
EPS (Basic)0.490.620.500.50(3.22)
EPS (Diluted)0.470.600.490.49(3.22)
Weighted Avg Shares20.05M20.2M20.08M19.99M20.1M
Weighted Avg Shares (Diluted)20.74M20.75M20.47M20.3M20.1M

Simulations Plus, Inc.

NASDAQ:SLP

Intrinsic Alpha fair value

Locked

Current Price

$18.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.